Moleculer genetic study of beta-micoseminoprotein in the prostage gland.

前列腺β-小核蛋白的分子遗传学研究。

• 批准号: 06404059
• 负责人: SAITO Yutaka
• 金额: $ 16.13万
• 依托单位: Nagasaki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (A)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-06404059/
• 关键词: prostate cancer; beta-microseminoprotein; gene mapping; mRNA; in situ hybridization; immunohistochemistry; Prognosis; tumor marker; 遺伝子座; 突然変異

1.We assigned the human beta-microseminoprotein (beta-MSP) gene to 10q11.2 with fluorescence in situ hybridization, and the data has shown that the gene is outside the previously identified LOH-regions (10p and 10q24*qter).2.In mutation analysis by single-strand conformational polymorphism analysis (SSCP), no aberrant bands were detected in 40 cancerous tissue samples analyzed.3.We analyzed the expression of both beta-MSP mRNA and its protein in biopsy specimens from 104 patients with untreated prostate cancer using both nonradioactive in situ hybridization and immunohistochemistry. Of the 104 specimens, 72 and 96 were negative for beta-MSP mRNA (69.2%) and beta-MSP (92.3%), respectively. Our results showed a lower level of expression of beta-MSP in prostate cancer tissue, compared with benign prostate tissue, and that this phenomenon may be mainly due to the presence of reduced levels of beta-MSP mRNA.4.To estimate the influence of beta-MSP mRNA expression and three possible prognosti … More c factors, i.e. , patient age, clinical stage and histological grade, on time to progression under endocrine therapy, survival analyzes were performed in Cox's proportional hazards regression model. Multivariate analysis of patients with stage D disease showed that beta-MSP mRNA expression was the only significant prognostic indicator for progression under endocrine therapy (p=0.0034). The presence of cells that express the beta-MSP transcript may be a novel indicator of potentially aggressive prostate cancers.5.To evaluate the usefulness of beta-MSP as a tumor marker for prostate cancer, we measured bound and free serum beta-MSP levels in 42 patients with non-metastatic prostate cancer preradiotherapy. Tumor stage, grade and free beta-MSP levels were not significant predictors of treatment outcome. Pretreatment PSA and the ratio of bound/free beta-MSP were significant predictors of relapse post radiotherapy on univariate analysis. beta-MSP in addition to PSA may be of prognostic value for patients receiving radiotherapy for non-metastatic prostate cancer. Less

1.我们将人类β-微球蛋白用荧光原位杂交技术将β-MSP基因定位于10q11.2，数据表明该基因位于先前鉴定的LOH区域之外（10 p和10 q24 *qter）。2.在单链构象多态性分析（SSCP）的突变分析中，在40例癌组织中未检测到异常条带。MSP mRNA及其蛋白在104例未经治疗的前列腺癌活检标本使用非放射性原位杂交和免疫组化。在104例标本中，分别有72例（69.2%）和96例（92.3%）β-MSP mRNA阴性。我们的研究结果表明，与良性前列腺组织相比，前列腺癌组织中β-MSP的表达水平较低，这种现象可能主要是由于β-MSP mRNA水平降低所致。 ...更多信息 c因素，即患者年龄、临床分期和组织学分级，在内分泌治疗下进展的时间，在考克斯比例风险回归模型中进行生存分析。D期疾病患者的多变量分析显示，β-MSP mRNA表达是内分泌治疗进展的唯一重要预后指标（p=0.0034）。表达β-MSP转录本的细胞的存在可能是潜在的侵袭性前列腺癌的一个新指标。5.为了评估β-MSP作为前列腺癌肿瘤标志物的有用性，我们检测了42例非转移性前列腺癌患者放射治疗前的结合和游离血清β-MSP水平。肿瘤分期、分级和游离β-MSP水平不是治疗结果的显著预测因子。在单因素分析中，治疗前PSA和结合/游离β-MSP比值是放疗后复发的显著预测因素。除PSA外，β-MSP可能对接受放射治疗的非转移性前列腺癌患者具有预后价值。少

项目成果

Sasaki,T.,et al.: "Assignment of the human β-microseminoprotein gene (MSMB) to chromosome 10q11.2" Cytogenetics and Cell Genetics.72(in press). (1996)

Sasaki, T., et al.：“将人类 β-微精蛋白基因 (MSMB) 分配到染色体 10q11.2”《细胞遗传学和细胞遗传学》72（出版中）。

Hyakutake H,Sakai H,Yogi Y,Tsuda R,Minami Y,Yushita Y,Kanetake H,Nakazono I,Saito Y: "Beta-microseminoprotein immunoreacitivity as a new prognostic indicator of prostatic carcinoma." Prostate. 22. 347-355 (1993)

Hyakutake H、Sakai H、Yogi Y、Tsuda R、Minami Y、Yushita Y、Kanetake H、Nakazono I、Saito Y：“β-微精蛋白免疫反应性作为前列腺癌的新预后指标。”

Yogi Y: "A monoclonal antibody assessment of the beta-microseminoprot ein expression in prostatic carcinoma as a prognostic indicator." Acta Med Nagasaki. 40. 13-17 (1995)

Yogi Y：“用单克隆抗体评估前列腺癌中 β-微小精蛋白的表达作为预后指标。”

Yogi, Y.: "A monoclonal antibody assessment of the beta-microseminoprotein expression in prostatic carcinoma as a prognostic indicator." Acta Medica Nagasakiensia. 40. 13-17 (1995)

Yogi, Y.：“用单克隆抗体评估前列腺癌中 β-微精蛋白表达作为预后指标。”

Sasaki,T.,et al.: "Assignment of the human β-microseminoprotein gene (MSMB) to chromosome 10q11.2" Cytogenetics and Cell Genetics. 72. 177-178 (1996)

Sasaki, T., et al.：“将人类 β-微精蛋白基因 (MSMB) 分配到染色体 10q11.2”《细胞遗传学和细胞遗传学》72. 177-178 (1996)。